<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02556047</url>
  </required_header>
  <id_info>
    <org_study_id>CRC332</org_study_id>
    <nct_id>NCT02556047</nct_id>
  </id_info>
  <brief_title>Evaluation of the Safety &amp; Performance of 2 Intradermal Safety Devices</brief_title>
  <official_title>A Clinical Investigation to Evaluate the Safety and Performance of Two Star Intradermal Safety Device (IDSD) Syringes in Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Surrey</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Surrey</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Several vaccinations are administered by the intradermal (ID) method where the vaccine is
      injected between layers of skin. The current technique required to do this can be difficult
      to learn and perform accurately, is slower to deliver than subcutaneous or intramuscular
      injections, and there is a risk that the injection will be given to too-deep skin layers or
      to underlying tissues, which might change the immune response. There is increasing interest
      in using ID administration for vaccines as it may be possible to achieve the same immune
      response with a smaller dose of vaccine. This could increase access to vaccines that are
      expensive or are only available in small quantities and therefore could have global health
      benefit for vaccine programs for diseases such as yellow fever and polio.

      Because of the potential global-health benefits of being able to give ID injections of
      vaccines easily, quickly and with relatively little training or experience, several novel
      devices are currently being developed to allow easy ID administration. Star Syringe have
      developed two novel intradermal safety devices that differ only in the length of the needle
      used. The current study will assess how the two new devices perform, compared to the
      traditional Mantoux test, using injections of saline into the upper arm. Twenty volunteers
      (18-60 years, male and female) will be recruited and attend a screening visit (1), an
      injection visit (2a) and have a follow up telephone call (2b). At the injection visit they
      will receive 3 injections in each arm (Mantoux and 2 device injections) and measurements will
      be performed.

      A subset of volunteers will be invited back to attend an additional visit (3a) which will be
      a repeat of visit 2 but with an ultrasound image taken of each injection site. There will be
      a follow up telephone call 24 hours later (3b).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Volunteers will be asked to attend Surrey CRC for two visits with a follow up telephone call.
      A subset of volunteers will be aske to attend an additional visit and follow up call.

      Visit 1 - Screening Visit (Day - 28 to -1) Visit 1 will take place up to 28 days prior to the
      injections being administered (Visit 2). At this visit consent will be taken and the
      following procedures performed: demography, medical history and concomitant medication, vital
      signs (blood pressure, heart rate, oral temperature), symptoms-directed physical examination
      including assessment of deltoid area, measurement of height and weight, blood sample taken
      for haematology and coagulation screen, completion of a medical health questionnaire.
      Inclusion/exclusion criteria will be assessed and volunteers that continue to be eligible
      will be invited back to attend Visit 2a.

      Visit 2a - Injection (Day 0) At Visit 2a, continuing eligibility will be assessed and both
      adverse events and concomitant medication will be recorded. Vital signs will be measured and
      if the volunteer is still eligible then they will be randomised onto the study.

      The volunteer will receive a total of 6 injections, 3 in each upper arm. In each arm there
      will be one Mantoux injection and 2 device injections (the same device or different). In
      total they will receive 2 Mantoux injections and 2 injections from each device. To maintain
      the blind of the study the volunteers will be asked to wear a blindfold during the
      injections. After each injection a number of measurements will be performed including
      assessing wheal size and wetness at the injection site as well as subjectively assessing
      pain. In addition the devices will be weighed before and after use.

      Following the injections, vital signs will be recorded again and volunteers will be
      discharged and provided with a diary card to complete over the following 24 hours. They
      should record side effects and any medications taken, including over the counter medications
      as well as any skin reactions.

      Visit 2b - Mandatory Follow Up telephone call (Day 1) The volunteer will be telephoned by a
      member of the study team 24 hours after the injection visit and both adverse events and
      concomitant medication will be recorded. Volunteers will be asked to return their diary cards
      to the CRC in the mail.

      A subset of volunteers will be invited back to attend Visits 3a and 3b.

      Visit 3a - Injection (Within days 7 to 28) At Visit 3a, continuing eligibility will be
      assessed and both adverse events and concomitant medication will be recorded. Vital signs
      will be measured and if the volunteer is still eligible then they will be randomised onto the
      study.

      The volunteer will receive a total of 6 injections, 3 in each upper arm. In each arm there
      will be one Mantoux injection and 2 device injections (the same device or different). In
      total they will receive 2 Mantoux injections and 2 injections from each device. To maintain
      the blind of the study the volunteers will be asked to wear a blindfold during the
      injections. After each injection a number of measurements will be performed including
      assessing wheal size and wetness at the injection site as well as subjectively assessing
      pain. At this visit, ultrasound echography will be performed for each injection site. In
      addition the devices will be weighed before and after use.

      Following the injections, vital signs will be recorded again and volunteers will be
      discharged and provided with a diary card to complete over the following 24 hours. They
      should record side effects and any medications taken, including over the counter medications
      as well as any skin reactions.

      Visit 3b - Follow Up telephone call (24 h after Visit 3a) The volunteer will be telephoned by
      a member of the study team 24 hours after the injection visit and both adverse events and
      concomitant medication will be recorded. Volunteers will be asked to return their diary cards
      to the CRC in the mail.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Diameter of wheal following each injection</measure>
    <time_frame>Within 2 minutes</time_frame>
    <description>To obtain data on wheal size for two versions of an investigational intradermal safety device and compare this to the 'gold-standard' of the Mantoux technique with needle and syringe (referred to as Mantoux N&amp;S)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Volume of fluid on skin following each injection</measure>
    <time_frame>Within 1 minute</time_frame>
    <description>To obtain data on 'wetness' of injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight of syringes pre filling</measure>
    <time_frame>Within 4 hours</time_frame>
    <description>To obtain data on pre- and post-injection weight of injectate in the injection devices.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight of syringes post filling</measure>
    <time_frame>Within 2 hours</time_frame>
    <description>To obtain data on pre- and post-injection weight of injectate in the injection devices.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight of syringes post injections</measure>
    <time_frame>Within 2 hours</time_frame>
    <description>To obtain data on pre- and post-injection weight of injectate in the injection devices.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events recorded</measure>
    <time_frame>Within 24 hours</time_frame>
    <description>Local and systemic safety events recorded. Local safety events will be skin reactivity (redness, hardness, swelling).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analogue Score for Pain</measure>
    <time_frame>Within 2 minutes of injections at visit 2a and visit 3a</time_frame>
    <description>Intensity of and comparative perceived pain during injection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Least painful injection</measure>
    <time_frame>Within 4 minutes</time_frame>
    <description>Following 3 injections on one arm the participant will be asked which was the least painful injection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Most painful injection</measure>
    <time_frame>Within 4 minutes</time_frame>
    <description>Following 3 injections on one arm the participant will be asked which was the most painful injection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ease of Use Questionnaire</measure>
    <time_frame>Within 1 week</time_frame>
    <description>Limited qualitative data on ease of use from the research nurses.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Depth of dermis</measure>
    <time_frame>Within 10 mins</time_frame>
    <description>Ultrasound echography of the wheal depth and diameter for two versions of an investigational intradermal safety device, compared with Mantoux N&amp;S</description>
  </other_outcome>
  <other_outcome>
    <measure>Thickness of dermis</measure>
    <time_frame>Within 10 mins</time_frame>
    <description>Ultrasound echography of the wheal depth and diameter for two versions of an investigational intradermal safety device, compared with Mantoux N&amp;S</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Syringe</condition>
  <arm_group>
    <arm_group_label>Injections</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Two injections of 0.1 ml sterile saline per injection using Star intradermal safety device 1.2mm needle length
Two injections of 0.1 ml sterile saline per injection using Star intradermal safety device 1.5mm needle length
Two injections of 0.1 ml saline per subject using Mantoux technique by N&amp;S</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Star Intradermal Safety Device</intervention_name>
    <description>Star Intradermal Safety Device 1.2mm needle length, Star Intradermal Safety Device 1.5mm needle length, Mantoux technique by N&amp;S</description>
    <arm_group_label>Injections</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male or female volunteers aged 18 to 60 years inclusive. Attempts will be made
             to achieve an equal gender ratio through appropriate screening procedures, but a
             failure to do so will not preclude analysis of the final data set.

          2. The volunteer is, in the opinion of the investigator, healthy on the basis of
             self-reported medical history, vital signs, a physical examination (including the skin
             overlying the deltoids of the upper arms), and the results of routine haematology and
             coagulation laboratory tests, with no active disease process that could interfere with
             the study endpoints.

          3. Body Mass Index â‰¥18.5 and &lt;29.5.

          4. The volunteer is able to read and understand the Informed Consent Form (ICF), and
             understand study procedures.

          5. The volunteer has signed the ICF and is willing to comply with study procedures.

          6. Available for follow-up for the duration of the study.

        Exclusion Criteria:

          -  1. Clinically significant psychiatric, cardiovascular, respiratory, hepatic, renal,
             gastrointestinal, endocrine, neurological (particularly myasthenia gravis),
             immunological, or haematological disease or abnormality, as determined by the study
             physician, which might interfere with consenting or self-recording of safety events.

             2. Presence of large or dark tattoos or other marking or abnormal variation in skin
             pigmentation in the area of the deltoids that would preclude measurement of six
             injection site wheals.

             3. Acute, self-reported needle phobia. 4. Regular use of anti-coagulant medication,
             non-steroidal anti-inflammatory drugs, topical or oral steroids, anti-histamines and
             opiates for longer than six months.

             5. Pregnant or lactating at any point during the study from screening to final follow
             up.

             6. Any condition that, in the investigator's opinion, compromises the volunteers'
             ability to meet protocol requirements or to complete the study.

             7. Unable to read and speak English to a fluency level adequate for the full
             comprehension of procedures required in participation and consent.

             8. Dermatological and other conditions likely to cause excessive soreness, bleeding or
             pain at the site of injection or subsequent scarring; these might include
             hyperkeratosis and bleeding disorders.

             9. Peripheral neuropathy, which might interfere with pain perception.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Lewis</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Surrey</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Surrey Clinical Research Centre</name>
      <address>
        <city>Guildford</city>
        <state>Surrey</state>
        <zip>GU2 7XP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 17, 2015</study_first_submitted>
  <study_first_submitted_qc>September 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2015</study_first_posted>
  <last_update_submitted>October 12, 2015</last_update_submitted>
  <last_update_submitted_qc>October 12, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

